1.
Axial codes and subcodes related to key assigment 1 (N = 196 students; N = 146 performed and readable tasks).
Axial codes and subcodes related to key assignment 2 (N = 196, N = 142 performed and readable tasks).
Axial codes and subcodes related to key assignment 3 (N = 196, T1: N = 123; T2: N = 121 performed and readable tasks).
CBP per cumulative year for daratumumab and pembrolizumab per vial.
2.
3.
CBP per cumulative indication for daratumumab and pembrolizumab per vial.
Scenario analysis for daratumumab using a cumulative cost-based price per year per vial.
Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial.
Implementation of indication-based pricing (10 th scenario) for daratumumab and pembrolizumab.
Input parameters for the base-case analysis.
Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation.
